Statin intolerance (SAMS): the AU general practice rechallenge approach

The problem with stopping statins on vague muscle aches

Statins are among the most effective and most studied cardiovascular medicines in history. A CTT Collaboration meta-analysis (Lancet 2022) covering more than 170,000 patients showed that every 1 mmol/L reduction in LDL-cholesterol reduces major cardiovascular events by approximately 22%. For a patient with established atherosclerotic disease, that translates to roughly a quarter reduction in heart attack and stroke risk per year.

Yet statin discontinuation rates in Australian general practice are substantial — and muscle symptoms are the most frequently cited reason. The tension between this reported intolerance and the cardiovascular protection being foregone is one of the most clinically consequential problems in general practice lipid management.

The nocebo evidence changes the conversation. The SAMSON trial (NEJM 2020) used a blinded n-of-1 design in 60 patients who had stopped statins because of muscle symptoms: symptom intensity scores were 90% as high on placebo as on active atorvastatin. The StatinWISE RCT (BMJ 2021) — 200 patients, six double-blinded periods (alternating atorvastatin 20 mg and placebo) — found no overall difference in muscle symptom scores between active drug and placebo. Pooled data from structured rechallenge studies suggests true statin-associated muscle symptoms (SAMS) affect 5–10% of users; the remainder is explained by nocebo, background musculoskeletal pain, and unrecognised reversible contributors.

The clinical imperative is clear: before permanently labelling intolerance, rule out reversible causes, have the nocebo conversation, and attempt a structured rechallenge.

A. Core clinical — the AU general-practice framework

Defining the severity spectrum

Statin intolerance requires formal definition: inability to tolerate two different statins (including at least one at the lowest starting dose), with objectively assessable symptoms resolving off-statin and recurring on rechallenge. Per the National Lipid Association (NLA) Statin Intolerance Panel 2014, this is a high bar — most patients who report “statin intolerance” have not yet met it.

SAMS severity	Symptoms	CK	Management
Mild	Myalgia; no functional impairment	Normal or <4× ULN	Reassure; structured rechallenge; continue or switch
Moderate	Myalgia with functional impairment	Normal or <4× ULN	Dose reduce; switch to rosuvastatin/pravastatin; alternate-day dosing
Severe	Proximal weakness + myalgia	>5× ULN	Stop statin; investigate; specialist referral if persistent
Rhabdomyolysis	Severe weakness, dark urine, AKI	>10× ULN	Emergency department immediately
IMNM (anti-HMGCR myopathy)	Persistent proximal weakness after cessation	Markedly elevated, persistent	Neurology/rheumatology; immunosuppression

Other intolerance phenotypes (less common): hepatic intolerance (ALT >3× ULN persistent); new-onset type 2 diabetes (~1 extra case per 1,000 patient-years on high-intensity statin — the cardiovascular benefit substantially outweighs this risk in high-risk patients); peripheral neuropathy (rare).

History to take

• Symptom pattern: bilateral, symmetric, proximal (thighs, buttocks, shoulders) — the classic SAMS distribution. Unilateral, distal, or joint-based symptoms are less typical and suggest another aetiology
• Temporal pattern: onset typically 1–12 weeks after starting or dose increase; resolution within 2–4 weeks of stopping; recurrence on rechallenge — this pattern must be documented to confirm intolerance
• Prior statin history: which statins, what doses, which symptoms, how long tried, any prior rechallenge attempts
• Drug interactions: review ALL concomitant medicines for CYP3A4 and OATP1B1 inhibitors — amiodarone, gemfibrozil, clarithromycin, erythromycin, diltiazem, verapamil, fluconazole, ciclosporin; note grapefruit juice with simvastatin or atorvastatin
• Reversible contributor screen: hypothyroidism history; vitamin D deficiency; alcohol intake (>2 standard drinks/day independently elevates CK); recent unaccustomed eccentric exercise (causes CK rise independent of statins); dehydration
• CV risk context: established atherosclerotic cardiovascular disease (ASCVD), familial hypercholesterolaemia (FH), type 2 diabetes, CKD — higher CV risk justifies greater persistence with rechallenge
• Nocebo risk factors: prior media exposure to statin side-effect narratives, family member’s adverse experience, health anxiety — identify early to frame the rechallenge conversation effectively

Examination

• Vital signs, BMI, hydration status
• Muscle examination: bilateral proximal strength (MRC grade); Trendelenburg sign and waddling gait suggest proximal myopathy
• Inspect for skin signs of inflammatory myopathy (heliotrope rash, Gottron papules) if weakness is prominent
• Thyroid palpation; slow-relaxing reflexes suggest hypothyroidism
• Cardiovascular and peripheral vascular examination — frame the benefit-risk discussion against actual CV risk

Investigations

First-line (every patient presenting with suspected SAMS):

• TSH — exclude hypothyroidism (TSH >10 mIU/L will reproduce myalgia and CK elevation that resolves with thyroxine; this is the most important reversible mimic)
• 25-hydroxyvitamin D — vitamin D deficiency is associated with statin myalgia in multiple observational studies; correct deficiency regardless; MBS item 66833 (restricted indications — statin myopathy is recognised)
• UEC + LFT — baseline renal and hepatic function
• Lipids and HbA1c — re-establish LDL baseline on and off statin; assess diabetes risk
• CK — not routine. Per eTG and NLA 2014: approximately 50% of SAMS have normal CK; routine CK checking generates false positives from exercise, alcohol, and ethnicity (African ancestry has a higher normal range). Check CK only when symptoms are severe, when weakness is present, when urine is dark, or when symptoms persist after cessation

Second-line (for persistent severe symptoms or CK >5× ULN off statin for >4 weeks):

• Anti-HMGCR antibody (specialist-ordered) — immune-mediated necrotising myopathy (IMNM) triggered by statin exposure but autoimmune in mechanism; persists after cessation and requires immunosuppression. Per Mammen NEJM 2016 — rare but diagnostically critical to identify
• ANA, ENA, myositis panel — to exclude polymyositis, dermatomyositis
• ESR/CRP — polymyalgia rheumatica in patients over 50 with proximal stiffness

Differential diagnosis to consider

Condition	Discriminating feature
Nocebo SAMS	Bilateral aches; similar intensity on n-of-1 placebo; high media/anxiety exposure
Hypothyroid myopathy	TSH elevated; slow relaxing reflexes; resolves with thyroxine
Vitamin D deficiency myopathy	25(OH)D <50 nmol/L; proximal weakness; responds to replacement
Polymyalgia rheumatica	Age >50; morning stiffness >45 minutes; ESR/CRP elevated; dramatic response to prednisone
Drug-interaction myopathy	CYP3A4/OATP1B1 inhibitor introduced before symptom onset
Exercise/overuse myalgia	Temporally related to unaccustomed eccentric exercise; not bilateral; resolves with rest
Anti-HMGCR IMNM	Persistent proximal weakness + markedly elevated CK after statin cessation; anti-HMGCR positive

B. Evidence appraisal — managing the nocebo and true intolerance

The structured rechallenge is the central intervention. Per NLA 2014 and eTG, the management sequence is:

Step 1 — address reversible contributors first. Treat hypothyroidism; replete vitamin D; reduce alcohol intake; stop CYP3A4/OATP1B1 inhibitors where possible; allow 4–6 weeks of recovery from unaccustomed exercise. Only then assess whether symptoms remain.

Step 2 — the nocebo conversation. Present the SAMSON data honestly: most people who think their statin caused their muscle aches find the same aches on a placebo. This is not dismissing the symptoms — which are real — but accurately attributing them. Most patients accept a structured rechallenge once they understand the trial evidence.

Step 3 — structured rechallenge sequence:

1. Washout 2–4 weeks; confirm symptom resolution
2. Rechallenge with rosuvastatin 5 mg daily or pravastatin 10–20 mg daily — both are hydrophilic with minimal CYP3A4 involvement, providing lower muscle exposure than lipophilic statins (simvastatin, atorvastatin)
3. If daily dosing causes symptoms: alternate-day or 2–3×/week dosing — e.g., rosuvastatin 5–10 mg Monday/Wednesday/Friday; per Backes Drug Saf 2016 intermittent dosing achieves 15–35% LDL reduction with better tolerability
4. Patient-blinded n-of-1 trial for nocebo-dominant presentations (SAMSON method): provide three sets of identical bottles — active, placebo, and empty — with a symptom diary; review patterns together at 8–12 weeks
5. Add ezetimibe 10 mg daily to maximise LDL reduction on any tolerated statin — provides an additional 15–20% LDL reduction

LDL targets guide how hard to push rechallenge. Per the Heart Foundation 2023 guideline:

• Very high risk (established ASCVD, secondary prevention): LDL <1.8 mmol/L; ≥50% reduction from baseline
• High risk (FH, T2DM with end-organ damage, severe CKD): LDL <2.6 mmol/L
• Moderate risk: LDL <3.4 mmol/L

The key principle: any tolerated dose on any statin is more cardiovascular protection than no statin. Even alternate-day low-dose rosuvastatin counts toward PBS eligibility for PCSK9 inhibitors if escalation is eventually required.

C. PBS prescribing and alternative agents

Statins (atorvastatin, rosuvastatin, simvastatin, pravastatin) — PBS general schedule; no Authority required for monotherapy.

Ezetimibe 10 mg — PBS Authority Required (Streamlined); approved when hypercholesterolaemia is inadequately controlled on maximum-tolerated statin, or when statin is contraindicated or not tolerated. Fixed-dose combinations with rosuvastatin, atorvastatin, and simvastatin are also available and Authority-accessible on the same criteria.

Bempedoic acid (Nilemdo; or Nustendi with ezetimibe) — TGA-approved; PBS Authority listing (verify current criteria at pbs.gov.au before prescribing, as eligibility criteria are actively evolving). Oral mechanism — ATP-citrate lyase inhibition, activated only in the liver (not muscle), which is why it lacks the muscle exposure of statins. CLEAR Outcomes NEJM 2023 — in 13,970 statin-intolerant high-risk patients, 13% relative reduction in major adverse cardiovascular events. Watch for gout (uric acid rises modestly), tendon rupture (rare signal), and minor eGFR reduction.

Evolocumab (Repatha) and alirocumab (Praluent) — subcutaneous PCSK9 inhibitors; 50–60% LDL reduction. PBS Authority Required (initial application by specialist; repeats as streamlined). Criteria: familial hypercholesterolaemia or established ASCVD with LDL above threshold on maximum-tolerated statin plus ezetimibe for ≥12 weeks. FOURIER NEJM 2017 — evolocumab; significant reduction in cardiovascular events in established CVD.

Inclisiran (Leqvio) — siRNA targeting PCSK9 mRNA; ~50% LDL reduction with dosing at 0, 3 months, then 6-monthly. PBS Authority listed for FH and established ASCVD with LDL above threshold on maximum-tolerated statin. The 6-monthly dosing is a meaningful adherence advantage for patients who struggle with daily oral agents.

Fenofibrate 145 mg — PBS general schedule; for mixed dyslipidaemia and hypertriglyceridaemia; modest LDL effect; acceptable with statin co-prescribing (in contrast to gemfibrozil, which is contraindicated with any statin).

What to avoid:

• Gemfibrozil + any statin — myopathy risk is multiplied; use fenofibrate if a fibrate is needed alongside a statin
• Red yeast rice with prescription statin — red yeast rice contains monacolin K, a naturally occurring lovastatin analogue; combining it with a prescription statin adds myopathy risk without adding a PBS benefit; treat red yeast rice as equivalent to a low-dose statin

D. Australian operations

MBS pathways:

• Standard GP attendances — items 23/36/44; telehealth 91790/92029/92060
• GPCCMP (items 965/967) — statin intolerance bundled with dyslipidaemia and absolute cardiovascular risk qualifies; plan elements include structured rechallenge documentation, LDL targets, lifestyle plan (Mediterranean diet, exercise, alcohol, weight, smoking cessation), specialist referral pathway, allied health (dietitian, exercise physiologist)
• Mental Health Care Plan (items 2715/2717) — eligible when nocebo-driven anxiety is a primary driver of non-adherence; CBT or ACT can address illness-belief drivers of medication refusal
• Specialist referral (lipid clinic, cardiology, neurology, rheumatology) — items 105/106

Specialist referral pathways:

Refer to a lipid clinic or cardiologist for:

• True intolerance of ≥2 statins in a patient with established ASCVD, FH, or LDL persistently above target
• Initiation of PCSK9 inhibitor or inclisiran (initial Authority application requires specialist)
• Complex polypharmacy or inherited lipid disorders

Refer to neurology or rheumatology for:

• Persistent proximal weakness off statin for >4 weeks — suspected IMNM (anti-HMGCR myopathy requires immunosuppression and specialist management)

Monitoring on therapy:

• At rechallenge or dose change: lipids + UEC + LFT at 4–12 weeks; CK only if symptomatic
• Stable on therapy: annual lipids; LFT and CK only if symptomatic
• On PCSK9 inhibitor or inclisiran: lipids at 4–12 weeks, then 6–12 monthly

E. Special populations

Women of childbearing potential: Statins are Category D in pregnancy (teratogenic in animal studies; small case series of adverse pregnancy outcomes) — stop statin when pregnancy is confirmed and restart postpartum. This is a planned, temporary discontinuation; the CV risk during pregnancy is rarely such that statins cannot be safely paused. Discuss a contraception and statin restart plan in advance for women with FH or high CV risk who are planning a pregnancy.

Older adults (>70 years): Age is a risk factor for true SAMS (reduced CYP3A4 activity, lower lean mass). Lower starting doses, hydrophilic statins, and alternate-day dosing are all appropriate. The cardiovascular benefit of statins in secondary prevention remains large even at older ages; do not routinely cease statins in patients >80 without a specific clinical indication.

Renal impairment: Rosuvastatin is renally cleared — maximum dose is 10 mg daily if eGFR 15–60, and 5 mg daily in Asian ancestry patients in the same eGFR range (due to higher plasma concentrations). Pravastatin is also affected by renal function; AMH dose-adjustment tables apply.

Asian ancestry patients: Higher plasma statin concentrations for a given dose compared with Caucasian patients (OATP1B1 genetic variants more prevalent; reduced body weight relative to Western populations). Rosuvastatin 5 mg and atorvastatin 10 mg are appropriate starting doses.

Established ASCVD — high rechallenge imperative: The absolute cardiovascular benefit is largest in patients who have already had a heart attack, stroke, or revascularisation. The case for persistent rechallenge is most compelling in this group; tolerance of any dose of any statin, even alternate-day low-dose, preserves meaningful protection.

When to escalate

Emergency — attend ED immediately when:

• Dark tea-coloured urine, severe proximal weakness, or CK >10× ULN — rhabdomyolysis
• Rapid onset of severe weakness in a statin user with a known CYP3A4 inhibitor recently added

Urgent specialist referral (within days to weeks):

• Persistent CK >5× ULN after statin cessation for >4 weeks — suspected IMNM (anti-HMGCR positive)
• Suspected polymyositis or dermatomyositis

Routine specialist referral:

• Confirmed intolerance of ≥2 statins in high-CV-risk patient (ASCVD, FH) — lipid clinic for PCSK9 inhibitor or inclisiran initiation
• Complex polypharmacy interaction driving intolerance not resolvable in general practice

What this article is and is not

This is general health information drawn from current Australian and international evidence — eTG, Heart Foundation 2023, AMH, NPS MedicineWise, RACGP, NLA Statin Intolerance Panel, NICE NG181, and landmark trials. It is not personal medical advice and does not create a doctor–patient relationship. PBS Authority criteria for ezetimibe, bempedoic acid, PCSK9 inhibitors, and inclisiran change — verify at pbs.gov.au before prescribing.

For consumer-friendly information: HealthDirect — Statins, NPS MedicineWise, Heart Foundation, Better Health Channel.

---

Sources cited

1. Therapeutic Guidelines (eTG) — Lipid modification and statin myopathy
2. Heart Foundation — Australian guideline for assessing and managing cardiovascular disease risk (2023)
3. Australian Medicines Handbook (AMH)
4. NPS MedicineWise — Statins
5. RACGP
6. National Lipid Association — Statin Intolerance Panel (J Clin Lipidol 2014)
7. NICE NG181 — Cardiovascular disease: risk assessment and reduction
8. SAMSON trial (NEJM 2020)
9. StatinWISE trial (BMJ 2021)
10. CTT Collaboration — statin adverse effects meta-analysis (Lancet 2022)
11. CLEAR Outcomes — bempedoic acid (NEJM 2023)
12. FOURIER — evolocumab (NEJM 2017)
13. Mammen AL — Anti-HMGCR myopathy (NEJM 2016)
14. Backes JM et al — Intermittent statin dosing (Drug Saf 2016)
15. PBS — statin, ezetimibe, PCSK9 inhibitor listings
16. HealthDirect — Statins
17. Heart Foundation — Cholesterol medicines
18. Better Health Channel — Cholesterol